Molecular mechanisms of Schisandra chinensis in treating depression-neuropathic pain comorbidity by network pharmacology and molecular docking analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: United States NLM ID: 7605074 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-7544 (Electronic) Linking ISSN: 03064522 NLM ISO Abbreviation: Neuroscience Subsets: MEDLINE
    • Publication Information:
      Publication: [New York?] : Elsevier Science
      Original Publication: Oxford, Elmsford, N. Y., Pergamon Press
    • Subject Terms:
      Schisandra*/chemistry ; Molecular Docking Simulation*/methods ; Network Pharmacology* ; Neuralgia*/drug therapy ; Neuralgia*/metabolism; Drugs, Chinese Herbal/pharmacology ; Drugs, Chinese Herbal/therapeutic use ; Humans ; Animals ; Depression/drug therapy ; Comorbidity ; Depressive Disorder/drug therapy ; Depressive Disorder/metabolism
    • Abstract:
      This study utilized network pharmacology and docking analyses to explore a groundbreaking therapeutic approach for managing the neuropathic pain and depressive disorder (NP/DD) comorbidity. Schisandra chinensis (SC), a common Chinese medicine, has demonstrated numerous beneficial effects in treating neuropsychological disorders. The main objective of this study was to identify potential bioactive components of SC and investigate their interactions with relevant target genes associated with NP/DD. To gain insights into the underlying molecular mechanisms, GO and KEGG analyses were conducted. Furthermore, molecular docking analysis was employed to validate the therapeutic relevance of SC's active ingredients. Seven bioactive components of SC, namely Longikaurin A, Deoxyharringtonine, Angeloylgomisin O, Schisandrin B, Gomisin A, Gomisin G, and Gomisin R, exhibited effectiveness in the treatment of NP/DD. From this list, the first five components were selected for further analysis. The analyses revealed a complex network of interactions between the targets of SC and NP/DD, providing valuable information about the molecular mechanisms involved in the treatment of NP/DD with SC. SC components demonstrated the ability to regulate pathways involving tumor necrosis factor (TNF), vascular endothelial growth factor (VEGF), and other growth hormones (GH). Overall, this study contributes to our understanding of the molecular mechanisms underlying the effects of SC in treating NP/DD. Further investigation is necessary to explore the therapeutic potential of SC as a viable strategy for NP/DD comorbidity. These findings lay a solid foundation for future research endeavors in this field, holding potential implications for the development of novel therapeutic interventions targeting NP/DD.
      Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 IBRO. Published by Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Depression; Molecular docking; Network pharmacology; Neuropathic pain; Schisandra chinensis
    • Accession Number:
      0 (Drugs, Chinese Herbal)
    • Publication Date:
      Date Created: 20240720 Date Completed: 20240823 Latest Revision: 20240823
    • Publication Date:
      20240826
    • Accession Number:
      10.1016/j.neuroscience.2024.07.023
    • Accession Number:
      39032805